R&D Pipeline

Latest Competitive Analysis of AbbVie Drug Pipeline

18 October 2023
2 min read

Since acquiring Allergan, AbbVie has experienced a period of stable performance, but this year has seen a significant decline in the performance of its two heavyweight drugs, Adalimumab and Ibrutinib. Fortunately, the newer generation drugs such as Risankizuma, Upadacitinib, Venetoclax, and Cariprazine have made a certain contribution to growth, so the overall performance has not been too bad, which is why the market value has generally remained around 250 billion.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of AbbVie.

In terms of R&D, there have not been many surprises. The best news includes CD20×CD3 bispecific antibody Epcoritamab getting approval, as well as daily dose formulation of JAK1 inhibitor Upadacitinib being approved, phase 3 results for IL23p19 monoclonal antibody Risankizumab's UC and Ps indications, and phase 3 results for migraine drug Atogepant. 

图形用户界面, 文本, 应用程序

描述已自动生成

In terms of bad news, aside from Ibrutinib withdrawing MZL&MCL indications, TNFα ADC drug ABBV-154 and RORγt inverse agonist Cedirogant have both been terminated, while the Parkinson's combination drug ABBV-951 has received a Complete Response Letter (CRL) from the FDA.

图形用户界面, 文本

描述已自动生成

Rivus Pharmaceuticals' HU6 2a trial showed positive outcomes in treating high BMI individuals with Non-alcoholic Fatty Liver Disease
Latest Hotspot
3 min read
Rivus Pharmaceuticals' HU6 2a trial showed positive outcomes in treating high BMI individuals with Non-alcoholic Fatty Liver Disease
18 October 2023
The 2a trial of Rivus Pharmaceuticals' experimental metabolic booster, HU6, yielded promising results in treating High BMI individuals with Non-alcoholic Fatty Liver Disease.
Read →
Finding the Complete Antibody Sequence Using a Known CDR Sequence: An Exploration with Patsnap Bio Sequence Database
Bio Sequence
2 min read
Finding the Complete Antibody Sequence Using a Known CDR Sequence: An Exploration with Patsnap Bio Sequence Database
18 October 2023
One can elucidate the entire antibody sequence by utilizing a known Complementarity-determining region (CDR) sequence in combination with the accessible Patsnap Bio Sequence Database.
Read →
Latest Competitive Analysis of Merck Sharp & Dohme Drug Pipeline
R&D Pipeline
2 min read
Latest Competitive Analysis of Merck Sharp & Dohme Drug Pipeline
18 October 2023
Merck's recent revenue performance remains steady, with the K drug continuing to grow and earning the title of "New Generation Drug King".
Read →
Avidity Biosciences presents encouraging results for AOC 1001, showing progress and long-term safety in multiple areas for Type 1 Myotonic Dystrophy patients
Latest Hotspot
4 min read
Avidity Biosciences presents encouraging results for AOC 1001, showing progress and long-term safety in multiple areas for Type 1 Myotonic Dystrophy patients
18 October 2023
Avidity Biosciences Reports Fresh Positive Results for AOC 1001, Showing Progress in Various Additional Functional Measures and Long-term Safety and Acceptability in Individuals with Type 1 Myotonic Dystrophy.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.